AltairTrading Analysis Report: MELI¶
Analysis date: 2026-09-28 · Model: gpt-6-astra · AI-generated, not financial advice.
Generated: 2026-09-28 19:55:45
V. Portfolio Manager Decision¶
Rating: Underweight
Executive Summary: For MELI, cap existing exposure at the lesser of 0.5x the portfolio's normal single-name allocation and a stricter concentration- and gap-loss-tested limit, exiting only if no residual position is tolerable. Verify holdings, live pricing, liquidity and event timing, then reduce excess promptly in orderly windows without waiting for a rebound or imposing a fixed 2–3-session schedule. If already within the limit, do not add or sell mechanically; if uninvested, remain uninvested, and do not initiate a short. Review at MELI's next verified earnings release or sooner on material developments, using 6.7% operating margin as a fundamental checkpoint; the supplied data do not support an executable trade price, numerical price target or protective stop.
Price Target: not provided
Time Horizon: Until MELI's next verified earnings release, with earlier review for material developments.
IV. Risk Management Team Decision¶
Aggressive Analyst¶
Aggressive Analyst: Neither the conservative nor the neutral analyst has spoken yet, so I’d open with this: MELI’s upside is real, but the bold move here is to sell down an oversized position—not to defend it simply because the growth story is compelling.
MELI grew Q2 revenue 49.8% year over year, and advertising may become a valuable higher-margin business. Yet operating income fell 17.2%, EPS fell 10.9%, and doubtful-account provisions rose 84.9% against 73% growth in loans receivable. That does not prove credit quality has deteriorated, but it leaves a lot for the next earnings release to establish. At 46.5 times trailing earnings and 30.6 times forward earnings, the supplied valuation already anticipates a substantial profit recovery. I would rather preserve capital to press the advantage when that recovery is visible than pay for it while margins are moving the other way. Reported Q2 free cash flow is encouraging, but $2.13 billion of operating cash flow came from working-capital changes; it is not a clean answer to the earnings concern.
I’d push back on two tempting responses. A full exit would discard MELI’s long-term commerce, payments and advertising upside while its monthly trend remains up. But doing nothing until earnings would leave an oversized position exposed to another disappointment: the September 28 close of $1,712.41 was below the 10-day EMA, 50-day SMA and 200-day SMA, with the weekly trend down. The completed TD-9 buy setup and $59.11 ATR warn against dumping shares indiscriminately into a sharp decline; they do not establish a reversal. Mixed, low-confidence social sentiment is no substitute for confirmation.
So my recommendation is SELL only the exposure above 0.5 times your standard single-name allocation: sell roughly half that excess in the first suitable liquid window and the rest over the following 2–3 sessions, subject to execution limits. If you are already at or below the cap, do not add; if uninvested, stay uninvested. Do not short MELI. With no live quote or holdings information, I cannot set an executable sale price or stop. Reassess after the next earnings release for improving margins, credit costs and price momentum—then the retained stake gives you a way to participate if the growth thesis starts converting into profit. Aggressive Analyst: I still favor SELL, but the high-reward case is for a deliberate trim, not a retreat from MELI. The opportunity is to stop giving an unproven earnings recovery an oversized claim on the portfolio while retaining a stake in a business whose Q2 revenue grew 49.8%.
To the conservative analyst: you’re right that 0.5 times a normal single-name allocation is a cap, not a guarantee of safety. If concentration or loss tolerance demands less, sell more; if even a small position is intolerable, exit. But making a full exit equally attractive for a portfolio that can bear a smaller position gives up meaningful upside. MELI’s provision growth is concerning, yet it does not establish worsening loan quality from the data supplied, and provision expense fell from about 14.1% of revenue in Q1 to 12.5% in Q2. The monthly trend remains up, while reported advertising momentum offers another potential route to better earnings conversion. Those are not reasons to keep an oversized position; they are reasons not to discard the entire growth option.
I also agree that the proposed 2–3-session sale is not a promise to carry risk through deteriorating conditions. It is a way to avoid making one poorly timed sale in a volatile stock. With MELI’s $59.11 ATR and completed daily TD-9 buy setup, a relief rally is plausible even though the weekly trend is down. Sell excess exposure in suitable liquid windows after checking a live quote; accelerate if market or Brazil-related event risk makes delay unacceptable. Don’t wait for a TD-9 bounce, and don’t mistake one for trend repair.
To the neutral analyst: your concentration and loss-budget test improves the sizing rule, but it should sharpen the SELL decision rather than turn it into an indefinite conditional discussion. Q2 operating margin fell from 12.2% to 6.7%, EPS fell 10.9%, and the supplied 30.6-times forward earnings multiple anticipates roughly 52% higher EPS than the trailing figure. Reported Q2 free cash flow of $3.22 billion is encouraging, but $2.13 billion of operating cash flow came from working-capital changes. That is too much unresolved earnings and cash-flow risk to leave excess MELI exposure untouched. You’re also right that waiting for unmistakable recovery could miss a repricing—that is precisely why I would retain a tolerable stake rather than sell everything. Mixed, low-confidence social sentiment does not strengthen the case for holding more.
My recommendation is SELL MELI exposure above the lesser of 0.5 times your standard single-name allocation and your actual risk limit: aim to sell roughly half the excess in the first suitable liquid window and the remainder over the following 2–3 sessions, adjusting to conditions. If already within that limit, do not sell mechanically or add; if uninvested, remain uninvested. The September 28 close of $1,712.41, below the cited moving averages, supports the direction—not an executable price or stop. Reassess after verified earnings show whether growth is finally converting into margins and sound credit performance. Aggressive Analyst: Conservative analyst, cash gives you the option to buy MELI later, but it does not guarantee you can rebuild a position before a sharp repricing. Q2 revenue grew 49.8%, and reported advertising momentum offers a plausible route to better earnings conversion. Neither proves a turnaround. They do, however, make a small, tolerable stake more valuable than a default full exit. Your credit warning strengthens the case for selling excess exposure: provisions rose 84.9% year over year, and Q2’s provision-to-revenue ratio remained above last year’s. But the decline from 14.1% in Q1 to 12.5% in Q2—and the absence of loan-performance detail—also mean the supplied data do not establish a credit collapse.
Neutral analyst, I agree that concentration and gap-loss tolerance must override a half-allocation cap. Where I push back is on letting execution become open-ended. MELI’s September 28 close was below the cited moving averages, the weekly trend was down, operating margin had fallen to 6.7%, and the 30.6-times forward earnings multiple priced in a substantial recovery. Those are reasons to reduce an oversized position now, not merely to keep discussing whether to do so. The daily TD-9 setup and $59.11 ATR justify orderly execution—not waiting for a bounce.
My recommendation remains SELL MELI exposure above the lesser of 0.5 times your standard single-name allocation and your portfolio’s actual loss limit. After checking holdings, a live quote and liquidity, aim to sell roughly half the excess in the first suitable window and the balance over the next 2–3 sessions if conditions permit. Accelerate if event risk or market conditions make delay imprudent; sell further or exit if even the retained stake breaches your risk budget. If already within the limit, do not sell mechanically or add; if uninvested, remain uninvested. That is the bolder trade-off: free capital from an unproven earnings recovery while keeping a measured claim on MELI’s growth upside. Aggressive Analyst: Conservative analyst, you’re right that no MELI stake is worth keeping if the portfolio cannot withstand a sharp loss. But for a portfolio that can bear a small position, cash and a retained stake are not equivalent. Cash can be redeployed later; it cannot participate in a sudden repricing if MELI’s commerce growth and reported advertising momentum start converting into earnings. The monthly trend was still up as of September 28. That is not proof of a turnaround, but it makes a full exit a costly default rather than the boldest response to risk.
Your credit objection is the strongest reason to sell the excess. Q2 provisions rose 84.9% year over year against 73% growth in the loan balance, and provisions were 12.5% of revenue versus 10.2% a year earlier. The decline from 14.1% in Q1 does not establish improving loan quality without performance data. Equally, the available data do not establish a credit collapse. I would pay for that uncertainty by cutting position size, not by automatically surrendering every claim on MELI’s upside.
Neutral analyst, I agree that a small stake is not inherently better than cash and that ATR cannot bound an earnings or Brazil-related gap. But “sell in suitable windows, with no timetable” risks becoming permission to leave an oversized position untouched. MELI added $3.38 billion of revenue year over year in Q2, yet the $1.07 billion increase in gross profit was more than consumed by $1.21 billion of additional operating expenses. Operating margin fell from 12.2% to 6.7%, while the supplied forward EPS figure is roughly 52% above trailing EPS. That mismatch calls for a decision on excess exposure now, not an open-ended wait for perfect conditions.
The technicals reinforce urgency without justifying a rushed order. The September 28 close of $1,712.41 was below the 10-day EMA, 50-day SMA and 200-day SMA, with the weekly trend down. The completed daily TD-9 buy setup and $59.11 ATR mean a bounce could make a single indiscriminate sale costly; they do not justify holding excess MELI in hope of one. Likewise, $3.22 billion of reported Q2 free cash flow deserves attention, but $2.13 billion of operating cash flow came from working-capital changes. Neither bullish retail labels nor that cash-flow figure resolves the earnings question.
My recommendation is SELL MELI exposure above the lesser of 0.5 times your standard single-name allocation and what your portfolio can tolerate through a sharp adverse move. Check holdings, a live quote and liquidity first. Aim to sell roughly half the excess in the first suitable liquid window and the rest over the following 2–3 sessions only if conditions permit; accelerate rather than carry excess through a material event. If even the retained stake exceeds your loss budget, sell further or exit. If already within the limit, do not sell mechanically or add; if uninvested, remain uninvested. No historical level here supplies an executable price or protective stop. The high-reward choice is to free capital from an unproven recovery while keeping a tolerable stake in MELI’s growth if that recovery arrives quickly. Aggressive Analyst: Conservative analyst, I agree that a retained MELI stake is not a free option, and I am not calling half an allocation safe. Test the position against the whole portfolio and a sharp gap, not the $59.11 historical ATR; sell further or exit if it fails that test. But for a portfolio that can bear a small stake, cash and continued participation are not interchangeable. MELI’s 49.8% Q2 revenue growth and reported advertising momentum give it a credible route to a rapid repricing, even though neither has yet produced the margin recovery investors need. Selling the excess while retaining tolerable exposure is the bolder allocation decision than making an all-or-nothing bet on when that recovery appears.
Your credit and balance-sheet objections strengthen the case for the sale, not necessarily for a full exit. Q2 provisions were 12.5% of revenue, above the year-earlier 10.2%, and loan-performance detail is missing. The 1.12 current ratio, $6.86 billion of net debt and restricted cash deserve scrutiny; they do not, without more detail, establish a liquidity crisis. Nor would I use the $3.22 billion of reported Q2 free cash flow to dismiss the risk when $2.13 billion of operating cash flow came from working-capital changes. The point is to stop giving those unresolved questions an oversized claim on the portfolio while keeping a measured claim on MELI’s growth.
Neutral analyst, you are right that selling only half the excess first could be too slow ahead of an event. That is a reason to accelerate when the risk warrants it, not to leave the sale without a working timetable. MELI’s September 28 close was below the cited moving averages, the weekly trend was down, and operating margin had fallen from 12.2% to 6.7%. At the supplied 30.6-times forward earnings multiple, leaving excess exposure in place while waiting for an ideal window is itself a consequential risk decision. The TD-9 setup argues against a careless order, not for waiting for a bounce.
I recommend SELL MELI exposure above the lesser of 0.5 times your normal single-name allocation and the amount your portfolio can withstand through a plausible sharp loss. Check holdings, a live quote and liquidity; aim to reduce roughly half the excess in the first suitable window and the balance over the next 2–3 sessions only if conditions permit. Accelerate rather than carry excess through material event risk. If even the retained stake breaches the loss budget, sell more or exit. If already within the limit, do not sell mechanically or add; if uninvested, remain uninvested. The September 28 price is historical, not an executable sale price or stop.